From Cell Line Development To Upstream Optimization: Enhancing Biologics Quality And Productivity

Efficient biologics manufacturing hinges on high-titer, high-quality cell lines. Samsung Biologics has significantly advanced Cell Line Development (CLD) using a transposase gene integration system. This optimized approach yields 5-10 times greater titers in the pool stage and 3-7 times higher titers in the clone stage compared to traditional methods, while also improving purity and stability (up to 60 PDL). Furthermore, their S-Tensify™ platform, incorporating N-1 perfusion, doubles productivity without compromising quality.

Recognizing that antibody functionality is key to therapeutic efficacy, Samsung Biologics developed the S-AfuCHO™ cell line, derived from their S-CHOice® host. This cell line produces fucose-free antibodies with markedly enhanced ADCC activity, boosting therapeutic potency.

To achieve optimal glycosylation, early clone selection employs high-throughput lectin assays to identify top antibody producers. These clones undergo further optimization via a modular glycosylation platform and Design-of-Experiment (DoE) strategies, enabling precise control over ADCC and CDC functions in Upstream Process development. This integrated strategy ensures both high productivity and enhanced therapeutic performance.

Discover how Samsung Biologics integrates these cutting-edge CLD and USP strategies to maximize both productivity and therapeutic effectiveness in the development of high-quality biologics.